In:
Diabetic Medicine, Wiley, Vol. 9, No. 4 ( 1992-05), p. 335-340
Abstract:
The pharmacokinetics of intranasal insulin containing a medium‐chain phospholipid (didecanoyl‐L‐alpha‐phosphatidylcholine) as absorption enhancer, was studied in normal volunteers by measuring plasma glucose, insulin, C‐peptide, and glucagon. Eleven fasting subjects received 4 U insulin intravenously, 6 U subcutaneously, or three doses intranasally (approximately 0.3 U kg −1 , 0.6 U kg −1 , 0.8 U kg −1 ) in random order on five separate days. Intranasal insulin was absorbed in a dose‐dependent manner with a mean plasma insulin peak 23 ± 7 (± SE) min after administration. Mean plasma glucose nadir was seen after 44 ± 6 min, 20 min later than following intravenous injection. Furthermore, intranasal administration of insulin resulted in a faster time‐course of absorption than subcutaneous injection, with significantly reduced intersubject variation ( p 〈 0.001). Bioavailability for the nasal formulation was 8.3% relative to an intravenous bolus injection when plasma insulin was corrected for endogenous insulin production estimated by C‐peptide. A dose‐dependent suppression of C‐peptide and stimulation of glucagon secretion occurred after intranasal administration of insulin. Nasal irritation from spraying was absent or slight.
Type of Medium:
Online Resource
ISSN:
0742-3071
,
1464-5491
DOI:
10.1111/dme.1992.9.issue-4
DOI:
10.1111/j.1464-5491.1992.tb01792.x
Language:
English
Publisher:
Wiley
Publication Date:
1992
detail.hit.zdb_id:
2019647-7
Permalink